1STAvailable delivers strong first quarter growth and strategically positioned to outperform in fiscal 2017
1stAvailable (ASX: 1ST) has delivered a strong first half performance from a financial and operational perspective, while also forging some promising client relationships.
The company is an Australian online healthcare portal that simplifies and facilitates digital interaction between health services and consumers. The group provides cloud-based solutions including online search and appointment booking services for healthcare providers, reducing waiting times for patients and helping to automate healthcare providers’ administrative services.
With healthcare services stretched it is not surprising to see 1ST continue its impressive growth trajectory.
The company’s monthly recurring revenue for the three months to September 30, 2016 was $193,000, representing year-on-year growth of more than 40%.
Furthermore, monthly new consumer registrations have increased by 400% to more than 20,000 a month since July 2015. This positions the company strongly in terms of generating robust recurring income.
However, we should remind readers that investment decisions should not be based on forward looking statements or historical share price performances alone. Investors should seek independent financial advice if considering this stock for their portfolio.
1ST branches out into new industries and expanded its position in dental
In tandem with today’s quarterly update, the company announced that it had negotiated a new subscription agreement with a major dental corporate client.
Under the agreement, the 1ST platform will be rolled out initially to their New South Wales dental centres which accounts for 130 dentists.
This represents a substantial increase in the company’s share of the dental market with its customer base already including Primary Health Care’s dental division and the Pacific Smiles group.
The company has also made impressive inroads into the optical healthcare market with its clients including high profile organisations such as Bupa Optical, The Optical Company and a major group of independent optometrists.
This area of the company’s business is expected to be a strong growth driver in the December quarter.
1ST’s services also extend to the luxury cosmetics market where new agreements have been negotiated with leading retailer, Napoleon Perdis which involves the rollout of its platform of 85 stores and six academies. This will assist in generating subscription revenue for the company.
These developments suggest fiscal 2017 will be an important transitionary period for the group, having established meaningful positions across the dental, optical and retail industries.
Substantial increase in recurring revenue points to strong growth in fiscal 2017
As highlighted by Managing Director, Klaus Bartosch, recurring revenue is a relatively accurate forward performance indicator, and with the company not far off generating $200,000 per month, 1ST is well-positioned to substantially outperform its fiscal 2016 annual revenue of circa $2 million.
Having ended the quarter with a cash balance of $5.6 million, 1ST looks to have the financial backing that will go a long way to finding its growth initiatives throughout the rest of fiscal 2017, including investment in building sales across its healthcare markets and introducing new products which will provide additional sources of income as well as revenue diversification.
Looking at near-term growth drivers, Bartosch said, “As subscription revenue grows, we increase the addressable base for our products which puts the patient first and will contribute to new transaction-based revenue”.
It is worth noting that 1ST’s net tangible assets per ordinary security as at June 30, 2016 was circa 2.9 cents, indicating that its recent trading range of approximately 5 cents doesn’t accurately reflect the underlying value of the business, as well as its growth potential.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.